Role of oral methotrexate, cyclosporine and acitretin in treatment of palmoplantar psoriasis (red coloured, painful, itchy, fissured lesions on hands and feet) and psoriasis vulgaris (red coloured, scaly, itchy, elevated lesions on skin over body)

Safety and efficacy profile of oral cyclosporine versus oral methotrexate versus oral acitretin in palmoplantar psoriasis and psoriasis vulgaris â?? A hospital based prospective investigator blind randomized controlled comparative study.

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2015/05/005830

Enrollment

120

Registered

2015-05-29

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Palmoplantar psoriasis and psoriasis vulgaris

Interventions

Intervention1: cyclosporine, acitretin, methotrexate: Cyclosporine given in dose of 2.5 to 5 mg/kg/day daily for 90 days Acitretin given in dose of 25 to 50 mg/day daily for 90 days Methotrexate given

Eligibility

Inclusion criteria

Inclusion criteria: A.Have given written consent before any treatment commenced. B.Be diagnosed to be suffering exclusively from Palmo-plantar psoriasis either by clinical examination or histopathology if required will be included in palmoplantar psoriasis group. C.Be diagnosed to be suffering from psoriasis vulgaris having more than 20% body surface area will be included in psoriasis vulgaris group. D.Have completed 18 years of age. E.Have to stop any other modality of treatment, two months prior to the inclusion in study. F.Be able and willing, in the view of investigator, to comply all study procedure.

Exclusion criteria

Exclusion criteria: A.Patient with hypersensitivity to drug or patient intolerant to the study medication. B.Pregnant and lactating patient. C.Patient with Unrealistic expectations. D.Not willing for regular follow up. E.Patient with clinically significant cardiovascular, haematological, pancreatic, metabolic neurological or any other laboratory anomaly, which in the judgement of investigator, would interfere in participation in study or proper evaluation. F.Patient on any other systemic drugs therapy which in the judgement of investigator may interfere with interpretation of results. G.Patient having history of tuberculosis or chest X-ray showing evidence of any infective pathology.

Design outcomes

Primary

Measure	Time frame
1.) 75% reduction in psoriasis area and severity index or modified psoriasis area and severity index 2.) 75% reduction in Body Surface area 3.) 75% reduction in psoriasis severity indexTimepoint: 90 days	—

Secondary

Measure	Time frame
1.) Improvement in quality of life by Dermatology quality of life index and palmoplantar quality of life indexTimepoint: 90 days	—

Countries

India

Contacts

Public ContactSamkit Shah

Krishna Institute of Medical Sciences

tapdia.raj@gmail.com9823087223

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026